548 related articles for article (PubMed ID: 8930810)
81. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
82. Real-time monitoring of phosphodiesterase inhibition in intact cells.
Herget S; Lohse MJ; Nikolaev VO
Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
[TBL] [Abstract][Full Text] [Related]
83. Cyclic nucleotide phosphodiesterases in cultured normal and RCS rat pigment epithelium: kinetics of cyclic AMP and cyclic GMP hydrolysis.
Kurtz MJ; Edwards RB; Schmidt SY
Exp Eye Res; 1987 Jul; 45(1):67-75. PubMed ID: 2820772
[TBL] [Abstract][Full Text] [Related]
84. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases.
Weiss HR; Gong GX; Straznicka M; Yan L; Tse J; Scholz PM
Can J Physiol Pharmacol; 1999 Jun; 77(6):422-31. PubMed ID: 10537228
[TBL] [Abstract][Full Text] [Related]
85. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
86. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
87. Effect of docosahexaenoic acid and eicosapentaenoic acid in the phospholipids of rat heart muscle cells on adrenoceptor responsiveness and mechanism.
Grynberg A; Fournier A; Sergiel JP; Athias P
J Mol Cell Cardiol; 1995 Nov; 27(11):2507-20. PubMed ID: 8596201
[TBL] [Abstract][Full Text] [Related]
88. Multiplicity within cyclic nucleotide phosphodiesterases.
Rybalkin SD; Beavo JA
Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
[No Abstract] [Full Text] [Related]
89. Aggregation states of cyclic nucleotide phosphodiesterase of murine thymocytes.
Sobolev AS; Rybalkin SD
Cell Biochem Funct; 1986 Jul; 4(3):205-11. PubMed ID: 3015450
[TBL] [Abstract][Full Text] [Related]
90. Cyclic nucleotide phosphodiesterase activity in patients with obstructive airways disease.
Polson JB; Krzanowski JJ; Goldman AL; Szentivanyi A
Allergol Immunopathol (Madr); 1982; 10(2):101-4. PubMed ID: 6125092
[TBL] [Abstract][Full Text] [Related]
91. Role of cyclic nucleotide phosphodiesterases in ischemic preconditioning.
Lochner A; Genade S; Tromp E; Opie L; Moolman J; Thomas S; Podzuweit T
Mol Cell Biochem; 1998 Sep; 186(1-2):169-75. PubMed ID: 9774198
[TBL] [Abstract][Full Text] [Related]
92. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
93. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
94. Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction.
Geoffroy V; Fouque F; Lugnier C; Desbuquois B; Benelli C
Arch Biochem Biophys; 2001 Mar; 387(1):154-62. PubMed ID: 11368177
[TBL] [Abstract][Full Text] [Related]
95. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
Thomas RE; Armstrong DT; Gilchrist RB
Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
[TBL] [Abstract][Full Text] [Related]
96. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes.
Méry PF; Pavoine C; Pecker F; Fischmeister R
Mol Pharmacol; 1995 Jul; 48(1):121-30. PubMed ID: 7623766
[TBL] [Abstract][Full Text] [Related]
97. Cyclic nucleotide derivatives as probes of phosphodiesterase catalytic and regulatory sites.
Erneux C; Couchie D; Dumont JE; Jastorff B
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():107-18. PubMed ID: 6326517
[TBL] [Abstract][Full Text] [Related]
98. Angiotensin-converting enzyme inhibition prevents myocardial infarction-induced increase in renal cortical cGMP and cAMP phosphodiesterase activities.
Clauss F; Charloux A; Piquard F; Doutreleau S; Talha S; Zoll J; Lugnier C; Geny B
Fundam Clin Pharmacol; 2015 Aug; 29(4):352-61. PubMed ID: 25939307
[TBL] [Abstract][Full Text] [Related]
99. Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium.
Smith CJ; Krall J; Manganiello VC; Movsesian MA
Biochem Biophys Res Commun; 1993 Jan; 190(2):516-21. PubMed ID: 8381278
[TBL] [Abstract][Full Text] [Related]
100. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta.
Lindgren S; Rascón A; Andersson KE; Manganiello V; Degerman E
Biochem Pharmacol; 1991 Jul; 42(3):545-52. PubMed ID: 1650216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
